Neurocrine Biosciences Inc at Jefferies London Healthcare Conference Transcript
London Healthcare Conference. Really enjoying it so far. I have the pleasure of hosting Neurocrine. With us, we have -- by the way, my name is Akash Tewari. I'm one of the biotech analysts here at Jefferies. Today, I have the pleasure of hosting Neurocrine. Joining us today is Kevin Gorman, CEO; Matthew Abernethy, CFO; and then finally, Kyle Gano, Chief BD and Strategy Officer. Obviously, Neurocrine has been a huge winner for investors this year. How much are you guys up 40%? Something really impressive performers versus the market.
And then I think for investors, it's interesting. I was sitting next to a long only. And they said, Akash, the way that health care investors look at the stock and the way that general slip to stock are totally different. We're always worried about what's going on in 2028, 2030 and all these kind of unknowable debates, what generalist tells me is, Akash, this company has 30% to 40% revenue and EPS acceleration. The PEG is too cheap. And I can't find companies like that in my portfolio. And that's what
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |